MetaCap

Rallybio Cash Flow Statement

NASDAQ: RLYBHealth CareBiotechnology: Pharmaceutical PreparationsUSD

15.47-0.05 (-0.32%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Rallybio free cash flow

In fiscal 2025, Rallybio generated -$29.8 million of operating cash flow. That left free cash flow of -$29.8 million, a free-cash-flow margin of -3474.7% of revenue.

Summary generated from market data by MetaCap's automated system. Methodology

Rallybio cash flow statement (annual)

Rallybio annual cash flow statement
Fiscal year (USD)FY 20252025-12-31FY 20242024-12-31FY 20232023-12-31FY 20222022-12-31FY 20212021-12-31FY 20202020-12-31
Net Income-8.98M-57.77M-74.56M-66.65M-47.01M-26.45M
Net Income growth (YoY)——————
Depreciation & Amortization92.00K131.00K150.00K167.00K109.00K62.00K
Stock-Based Compensation5.31M7.99M10.92M9.50M3.65M704.00K
Change in Working Capital-4.19M-258.00K4.28M-936.00K-3.78M2.12M
Operating Cash Flow-29.81M-49.28M-60.27M-57.28M-45.53M-22.04M
Capital Expenditures—0-12.00K-54.00K-333.00K-137.00K
Investing Cash Flow47.27M33.49M27.66M-112.17M-2.33M-2.07M
Financing Cash Flow16.00K5.20M143.00K51.08M82.97M144.89M
Net Change in Cash17.47M-10.59M-32.46M-118.38M35.10M120.78M
Free Cash Flow-29.81M-49.28M-60.28M-57.34M-45.87M-22.18M

This table shows 6 annual periods of Rallybio's cash flow statement, from FY 2025 back to FY 2020, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow RLYB's reporting calendar. What is a cash flow statement?

More financial data